Tenax Therapeutics

TENX · NASDAQ

$1.63−$0.01 (−0.61%)TodayMarket closed · Oct 21, 4:01 AM ET

Prev close $1.64

About TENX

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company is headquartered in Chapel Hill, North Carolina and currently employs 14 full-time employees. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Employees: 14
Headquarters: Chapel Hill, North Carolina
Listed: Oct 28, 1993
Sector: Health Care
Industry: Biotechnology
Website: tenaxthera.com

Leadership

Tenax Therapeutics executives
Name	Title	Since	Age
Gerald Proehl	—	—	66
Christopher Giordano	—	2021	51
Thomas Mcgauley	—	—	52
Stuart Rich	—	2021	75
June Almenoff	—	—	68
Michael Davidson	—	—	68
Declan Doogan	—	—	71
Robyn Hunter	—	—	63

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Tenax Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
Orion B ORNBV.HE	Supplier and customer	FI	-0.46

Similar companies

Companies in the same industry as Tenax Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.